BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29883750)

  • 1. Antitumor activity of nanoliposomes encapsulating the novobiocin analog 6BrCaQ in a triple-negative breast cancer model in mice.
    Sauvage F; Fattal E; Al-Shaer W; Denis S; Brotin E; Denoyelle C; Blanc-Fournier C; Toussaint B; Messaoudi S; Alami M; Barratt G; Vergnaud-Gauduchon J
    Cancer Lett; 2018 Sep; 432():103-111. PubMed ID: 29883750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells.
    Sauvage F; Franzè S; Bruneau A; Alami M; Denis S; Nicolas V; Lesieur S; Legrand FX; Barratt G; Messaoudi S; Vergnaud-Gauduchon J
    Int J Pharm; 2016 Feb; 499(1-2):101-109. PubMed ID: 26721724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
    Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
    Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer.
    Dunne M; Dou YN; Drake DM; Spence T; Gontijo SML; Wells PG; Allen C
    J Control Release; 2018 Jul; 282():35-45. PubMed ID: 29673642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Crystal Study, and Anti-Proliferative Activity of Some 2-Benzimidazolylthioacetophenones towards Triple-Negative Breast Cancer MDA-MB-468 Cells as Apoptosis-Inducing Agents.
    Abdel-Aziz HA; Eldehna WM; Ghabbour H; Al-Ansary GH; Assaf AM; Al-Dhfyan A
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer.
    Doddapaneni R; Patel K; Chowdhury N; Singh M
    Exp Cell Res; 2016 Aug; 346(1):65-73. PubMed ID: 27177833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostics with Hybrid Liposomes in an Orthotopic Graft Model Mice of Breast Cancer.
    Ichihara H; Okumura M; Tsujimura K; Matsumoto Y
    Anticancer Res; 2018 Oct; 38(10):5645-5654. PubMed ID: 30275183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J; Chen X; Ward T; Pegram M; Shen K
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo.
    Hsieh MT; Chang LC; Hung HY; Lin HY; Shih MH; Tsai CH; Kuo SC; Lee KH
    Eur J Med Chem; 2017 May; 131():141-151. PubMed ID: 28319780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer.
    Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Zhao Y; Yan Y; Hu YJ; Wu JS; Lu WL
    Oncotarget; 2015 Nov; 6(34):36625-42. PubMed ID: 26429872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
    Yang M; Teng W; Qu Y; Wang H; Yuan Q
    Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
    Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
    Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
    BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery.
    Audisio D; Messaoudi S; Cegielkowski L; Peyrat JF; Brion JD; Methy-Gonnot D; Radanyi C; Renoir JM; Alami M
    ChemMedChem; 2011 May; 6(5):804-15. PubMed ID: 21374821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The flavonoid TL-2-8 induces cell death and immature mitophagy in breast cancer cells via abrogating the function of the AHA1/Hsp90 complex.
    Liu HJ; Jiang XX; Guo YZ; Sun FH; Kou XH; Bao Y; Zhang ZQ; Lin ZH; Ding TB; Jiang L; Lei XS; Yang YH
    Acta Pharmacol Sin; 2017 Oct; 38(10):1381-1393. PubMed ID: 28504248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLR 125 Auger Electrons for the Targeted Radiotherapy of Triple-Negative Breast Cancer.
    Grudzinski J; Marsh I; Titz B; Jeffery J; Longino M; Kozak K; Lange K; Larrabee J; Weichmann A; Moser A; Bednarz B
    Cancer Biother Radiopharm; 2018 Apr; 33(3):87-95. PubMed ID: 29641256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.